Associations between statins and COPD: a systematic review
Claudia C Dobler*1,2, Keith K Wong1 and Guy B Marks1,2,3

Address: 1Woolcock Institute of Medical Research, Sydney, New South Wales, Australia, 2Department of Respiratory Medicine, Liverpool Hospital, Sydney, New South Wales, Australia and 3South Western Sydney Clinical School, University of New South Wales, Sydney, Australia
Email: Claudia C Dobler* - c.dobler@unsw.edu.au; Keith K Wong - keithw@woolcock.org.au; Guy B Marks - g.marks@unsw.edu.au
* Corresponding author

Abstract

Background: Statins have anti-inflammatory and immunomodulating properties which could possibly influence inflammatory airways disease. We assessed evidence for disease modifying effects of statin treatment in patients with chronic obstructive pulmonary disease (COPD).

Methods: A systematic review was conducted of studies which reported effects of statin treatment in COPD. Data sources searched included MEDLINE, EMBASE and reference lists.

Results: Eight papers reporting nine original studies met the selection criteria. One was a randomized controlled trial (RCT), one a retrospective nested case-control study, five were retrospective cohort studies of which one was linked with a case-control study, and one was a retrospective population-based analysis. Outcomes associated with treatment with statins included decreased all-cause mortality in three out of four studies (OR/HR 0.48–0.67 in three studies, OR 0.99 in one study), decreased COPD-related mortality (OR 0.19–0.29), reduction in incidence of respiratory-related urgent care (OR 0.74), fewer COPD exacerbations (OR 0.43), fewer intubations for COPD exacerbations (OR 0.1) and attenuated decline in pulmonary function. The RCT reported improvement in exercise capacity and dyspnea after exercise associated with decreased levels of C-reactive protein and Interleukin-6 in statin users, but no improvement of lung function.

Conclusion: There is evidence from observational studies and one RCT that statins may reduce morbidity and/or mortality in COPD patients. Further interventional studies are required to confirm these findings.

Background

Chronic obstructive pulmonary disease (COPD) is a common disease with a high burden to society on a worldwide scale [1]. Only smoking cessation [2] and long-term oxygen therapy, in patients with resting hypoxemia while awake [3,4], clearly alter prognosis for survival or decline in lung function. The lack of potent treatment options for COPD patients contrasts with the development of new treatments in other high burden chronic diseases like cardiovascular disease. Several drugs, in particular statins, have been shown to improve prognosis after acute coronary events during the last 20 years [5].

Recently statins have emerged as a possible disease modifying agent in COPD. The rationale for this at least partly derives from the fact that the pathogenesis of COPD involves inflammatory processes [6], and persistent systemic inflammation seems to be present even in patients...
with stable COPD who do not currently smoke [7]. Lee et al. showed that simvastatin ameliorated the structural and functional derangement of rat lungs caused by cigarette smoking, partly by suppressing inflammation and matrix metalloproteinase-9 induction and preventing pulmonary vascular abnormality [8]. Statins possess pleiotropic effects in addition to their conventional lipid-lowering properties including anti-inflammatory, antioxidant, anti-thrombogenic and vascular function-restoring actions [9-11]. For example they have been shown to have a beneficial effect in sepsis and pneumonia [12,13].

There are reports from observational studies that statins may reduce morbidity and mortality in COPD patients. Whether statins have a beneficial effect in COPD patients by primarily reducing cardiovascular complications or because they exhibit an action directly targeting pulmonary inflammation is, however, a matter of controversy. We conducted a systematic review to find evidence for our hypothesis that statin treatment has a disease modifying effect in patients with COPD and improves a) morbidity and b) mortality.

**Methods**

**Identification and selection of papers**

We searched the published English-language literature to identify studies that examined the effect of statins in patients with COPD. We searched two electronic databases: MEDLINE through OvidSP and PubMed (1950-31st October 2008) and EMBASE through OvidSP (1980-31st October 2008). The following search terms were used to identify citations relevant to statins:

- statins,
- hydroxymethylglutaryl-CoA reductase inhibitors,
- lipid/cholesterol lowering therapy/drugs/medication, and
- generic names of different types of statins

The following search terms were used to identify citations relevant to COPD:

- [chronic] obstructive pulmonary/respiratory/lung disease,
- COPD,
- airflow obstruction, and
- airway/lung/pulmonary inflammation

For details concerning the search strategy see Additional file 1. Additionally the reference lists of identified publications were searched. The search strategy was discussed and agreed upon by all authors, and advice was sought from a medical librarian experienced in medical informatics. The search was limited to articles on research in humans. All types of studies were included.

On reviewing the selected titles and abstracts we retained publications reporting clinical or laboratory outcome measurement in COPD patients treated with statins. Studies in which outcomes of treatment with statins were examined for a subgroup of subjects with COPD or obstructive pulmonary function were also included. Only articles reporting original data were retained; abstracts, editorials and letters were excluded.

**Review of studies**

The initial database created from the electronic searches of MEDLINE and EMBASE was compiled with EndNote and all duplicate citations were eliminated. Two reviewers (CCD and KKW) screened these citations by title and abstract review to identify potentially relevant studies. The full text of these papers were then retrieved and reviewed to confirm eligibility. Disagreements between the reviewers were resolved by consensus. Studies were eligible for inclusion if they were primary articles reporting an association between statin treatment and clinical or laboratory outcomes in COPD patients.

**Data extraction**

We extracted information on study objective, study design, inclusion and exclusion criteria for participants, COPD definition for the study purpose, details on statin treatment, use of corticosteroids, smoking status, cardiovascular comorbidities in participants, duration of follow-up, and outcome measurements. Specific attention was given to the inclusion or exclusion of patients with asthma. Details on statin treatment included type of statin, dosage, duration of treatment and adherence to treatment.

**Assessment of methodologic quality of included studies**

The RCT was assessed for evidence of concealed randomization, similarity of the randomized groups at baseline, standardization of non-intervention treatment strategies between treatment groups, blinding of patients and investigators, number of crossovers, intention-to-treat analysis, follow-up to the defined outcome, and generalizability of the conclusions of the trial to other populations [14]. Observational studies were evaluated for internal validity based on adequate description of patient characteristics (including age, definition of COPD and cardiovascular comorbidities), adequate description of treatment strategy (statin type, dosage, duration of treatment) and follow-up. They were also assessed for external validity using a qualitative determination of the degree to which the findings of the study could be generalized to other populations [15].
Results
Overall, 785 citations were identified, from which 21 articles were selected for review (Fig 1). Of these, 10 were excluded because they were reviews, letters or comments. Three original articles did not meet the inclusion criteria. One study, which examined the effect of statin use on lung function in elderly patients with various smoking histories, was excluded, because there was no specific analysis for patients with COPD or obstructive pulmonary function test findings published [16]. We excluded one study that examined the effect of statins in patients with asthma [17], and another study that reported the effects of statin use on lung transplant recipients [18]. A total of 8 papers reporting 9 studies met the inclusion criteria (Table 1). They were all published between 2006 and 2008 and reported effects of statin treatment on patients with COPD.

Only one study was a randomized controlled trial (RCT). The other studies were analyses of observational data and included one nested case-control study, five historical cohort studies of which one was linked with a case-control study, and one ecological study.

Treatment outcomes
Data on the association of statin treatment with continuous outcome variables are presented in Table 2. Effect estimates for binary outcomes are presented in Fig 2. Three cohort studies reported decreased all-cause mortality in patients treated with statins, whereas no difference in all-cause mortality between statin users and non-statin users was found in one cohort study. Another cohort study and the linked case-control study showed a decrease in deaths attributed to COPD. The ecological analysis found less COPD mortality in areas with high statin use. A reduction in incidence of respiratory-related urgent care with statin use was found in two studies. One cohort study found fewer COPD exacerbations and fewer required intubations secondary to COPD in patients who were taking statins. One observational study reported attenuated decline in pulmonary function parameters in statin users, whereas the only interventional study did not find a difference in lung function in statin users after six months of treatment. However, the RCT reported improvement in exercise capacity and dyspnea after exercise associated with decreased levels of CRP and IL-6 in statin users.

Due to a high degree of heterogeneity of study designs and outcome measurements a meta-analysis of the reviewed data was not feasible.

Assessment of methodologic quality of included studies
The RCT [19] described allocation concealment (sealed envelopes) and similarity of the groups at baseline. Treatment strategies were standardized between the treatment groups, patients and investigators were blinded and an intention-to-treat analysis was performed. Subject retention to outcome assessment was 86% after 6 months (18 out of 125 patients withdrew during the study).

The observational studies that were analysed all had adequate description of patient characteristics including details on patients’ age and definition of COPD for study purposes. All studies (except for the study by Frost et al. [20]) described cardiovascular comorbidities. Descriptions of treatment strategies lacked details regarding type of statin used and dosage. The study by van Gestel et al. [21] had the most comprehensive description of treatment strategy and also documented very good follow-up of 96%. The issue of external validity or generalizability of the findings is dealt with in the next section.

Key differences between included studies
Definition of COPD
Different criteria were applied for definition of COPD. The majority of studies relied on a patient chart diagnosis of COPD. Those studies using health system data identified COPD based on one or more of the following recorded codes from the International Classification of Disease: ICD-10 J41–44 or ICD-9 490–496 [20,22,23]. In one of these studies spirometric data were also available and only 88% had a FEV1/FVC ratio < 0.7 [22], which means that 12% of the cohort patients with spirometry results available did not meet the GOLD criteria [24] for the definition of COPD. Patients with COPD where identified through medication use in one study [25]. The cohort study by Keddissi et al. [26], the study by van Gestel et al. [21] and the RCT [19] applied lung function criteria (FEV1/FVC<70%) for the definition of obstructive lung disease. However, in the study by Keddissi et al. there was a discrepancy between 169 patients (40%) that had a COPD diagnosis based on information from medical records, compared to 319 patients (76%) who were found to have obstructive baseline spirometry. Hence, “COPD populations” analysed in those studies that did not use lung function criteria may differ from people with COPD defined in accordance with GOLD criteria [24].

Exclusion of asthma patients
Three studies used specific exclusion criteria to avoid inclusion of subjects who had a primary diagnosis of asthma. Mancini et al. [25] excluded all patients who had used at least one prescription of an inhaled steroid, nasal steroid, and other drugs including nedocromil, ketotifen, and cromoglycate during the year preceding cohort entry. However, they performed a separate analysis for a COPD cohort including users of oral or inhaled steroids (but not nasal steroids). Results were similar when steroid users were included. In the study by Keddissi et al. [26] patients with a clinical history of asthma were excluded. Yet, as the
| Author, place, date of publication | Study design | Study purpose | Statin exposed group | Controls | Outcome measurements |
|-----------------------------------|-------------|--------------|---------------------|----------|---------------------|
| Lee T-M, et al., Taiwan, 2008[19] | Randomized, double-blinded, placebo-controlled trial | To investigate whether pravastatin administration is effective in improving exercise capacity in patients with COPD, and whether baseline or serial changes in hs-CRP over time are associated with corresponding changes in exercise capacity. | n = 62 patients with clinically stable COPD, received pravastatin (40 mg/day) over a period of 6 months (randomly assigned, double blind). | n = 63 patients with clinically stable COPD, received placebo over a period of 6 months (randomly assigned, double blind). | Exercise capacity CRP/IL-6 Secondary outcome measurements: Lung function Borg dyspnea score after exercise tests |
| Blamoun AI et al, USA, 2008 [27] | Cohort study | To assess the rate of COPD exacerbations and intubations in COPD patients taking statins | n = 90 patients with primary or secondary diagnosis of COPD who were taking statins at the time of hospital admission and during the 1-year follow-up | n = 95 patients with primary or secondary diagnosis of COPD who were not taking statins at the time of hospital admission and during the 1-year follow-up | COPD exacerbations Intubations secondary to COPD exacerbation |
| Van Gestel YR et al., Netherlands, 2008 [21] | Cohort study | To examine the relation between statins and mortality (within 30 days and 10 years) in a group of patients who underwent surgery for peripheral arterial disease and compare results in those with versus without associated COPD | COPD group: n = 330 COPD patients who underwent elective vascular surgery and who did use statins | COPD group: n = 980 COPD patients who underwent elective vascular surgery and who did use statins | All-cause mortality, short- and long-term (within 30 days and 10 years of follow-up respectively) |
| Søyseth V et al., Norway, 2007[22] | Cohort study | To determine whether statins alone or in combination with inhaled steroids improve survival after COPD exacerbation | n = 118 patients with a diagnosis of COPD exacerbation at hospital discharge who were taking statins at the time of discharge | n = 736 patients with a diagnosis of COPD exacerbation at hospital discharge who were not taking statins at the time of discharge | All-cause mortality |
| Frost FJ et al., USA, 2007 [20] | Cohort study, and separate case-control studies (for influenza and COPD deaths) | To assess whether statin users have reduced mortality risks from influenza and COPD | Cohort study: n = 19,058; patients with statin exposure Case control study: n = 207; COPD deaths (in hospital) | Cohort study: n = 57,174; patients with no history of statin therapy Case-control study: n = 9,622; surviving patients with either an inpatient or outpatient diagnosis of COPD | Mortality from COPD (and influenza, not included in this review) |
Table 1: Characteristics of included studies (Continued)

Keddissi JL et al., USA, 2007 [26] Cohort study To assess the ability of statins to preserve lung function in current and former smokers and to reduce the incidence of respiratory-related urgent care

- n = 215; statin users who were smokers or ex-smokers and had abnormal baseline spirometry (majority with obstructive spirometry findings, but restrictive findings also included).
- n = 203; non-statin users who were smokers or ex-smokers and had abnormal baseline spirometry (obstruction or restriction)

- Lung function (annual decline in FEV1 and FVC)
- Respiratory-related ED-visits and hospitalizations

Mancini GB et al., Canada, 2006 [25] Nested case-control study (time-matched) To determine if statins, angiotensin-converting enzyme-inhibitors and angiotensin receptor blockers reduce total mortality, COPD hospitalisations and myocardial infarctions in COPD patients

- Two distinct COPD cohorts: 1) n = 2983 (sum of cases analysed for different endpoints, n = 3231 when steroid users included), high cardiovascular risk cohort (COPD patients having undergone coronary revascularization)
- 2) n = 7617 (sum of cases analysed for different endpoints, n = 8240 when steroid users included), low cardiovascular risk cohort (COPD patients without previous myocardial infarction and newly treated with nonsteroidal anti-inflammatory drug)

- COPD hospitalizations
- Myocardial infarction
- All-cause mortality

Ishida W et al., Japan, 2007 [23] Ecological analysis To assess effects of statin use on mortality from major causes of death (cardiovascular diseases, COPD, pneumonia etc.)

- COPD deaths in the >65 yrs old population in each of the 47 prefectures of Japan
- No control

- Mortality from COPD (and other major diseases), related to statin sales in the same area
authors of the paper state, it was still possible that some included patients had an asthmatic component to their lung disease, particularly when taking into account that 3–6% of all cohort patients were receiving leukotriene inhibitors. Lee et al. [19] excluded patients with one or more of the following features (possibly indicating a diagnosis of asthma): a history of perennial allergic rhinitis, periodic wheezing and an improvement in FEV1 of >15% after inhalation of a bronchodilator.

Concomitant use of steroids
A number of studies examined whether the inclusion of corticosteroid-steroid users altered the findings. Other simply reported on the use of corticosteroids in the study population. The studies by Mancini et al. [25] and Søyseth et al. [22] showed that use of inhaled corticosteroids did not modify the effect of statins on mortality (or the other outcomes measured in Mancini’s study). However, the study by Søyseth et al. reported an additive benefit on mortality when statins and inhaled corticosteroids were combined. In the lung function study by Keddissi et al. [26] there was no difference in the use of inhaled or systemic corticosteroids or immunosuppressive therapy between the statin group and the controls. For the whole cohort (including 76% with obstructive pulmonary function test findings and 24% with restrictive pulmonary function test patterns) the change in FEV1 was associated with both statin use and the use of steroids. The change in FVC was associated with statin use, the use of nonsteroidal anti-inflammatory drugs/aspirin and the use of β-blockers. In the RCT from Taiwan [19] 48% of patients in the pravastatin group and 52% in the placebo group were described as steroid dependent at baseline. All medications for COPD were kept constant throughout the study period of 6 months. Modification of the effect of statins by corticosteroids was not evaluated.

Smoking status
The smoking status of participants was reported in 5 studies. The study by Søyseth et al. [22] included 6.9% of
patients who had never smoked, 37.5% former smokers, 51.8% current smoker and 3.9% had missing data. No definition for who qualified as former smoker (duration of smoking abstinence) was given. The age-adjusted relative mortality was lower in statin users than nonusers in the subgroups of never smokers and current smokers, but not former smokers. Keddissi et al. [26] excluded never smokers in their study. 65% of their study participants were ex-smokers (defined as patients that quit smoking at least 6 months prior to the last pulmonary function test), 35% were current smokers. The beneficial effect of statins on lung function decline was apparent in both the current smoker and the ex-smoker groups with no significant difference between the groups. The cohort study that analysed exacerbations and intubations for exacerbations of COPD [27], the study that looked at

Table 2: Association of statin treatment with continuous outcome variables

| Study                          | Outcome                                                                 | Parameter estimate and 95% confidence interval |
|-------------------------------|-------------------------------------------------------------------------|-----------------------------------------------|
| **Mortality 2° to COPD**      |                                                                         |                                               |
| Ishida W, et al., Japan, 2007 [23] | Decreased mortality 2° to COPD in statin users                          | Inverse correlation between statin prescriptions dispensed and mortality due COPD by prefecture, p < 0.0001 |
| **Respiratory-related urgent care** |                                                                         |                                               |
| Keddissi JI, et al., USA, 2007 [26] | Reduction in respiratory-related emergency-department-visits and/or hospitalizations in statin users | Incidence of respiratory related urgent care, obstructive spirometry group 0.12 ± 0.29/patient-yrs in statin users versus 0.19 ± 0.32/patient-yrs in control, p = 0.02 |
| **Lung function**             |                                                                         |                                               |
| Keddissi JI, et al., USA, 2007 [26] | Lower decline in FEV1 and FVC/yr in statin users                        | Obstructive spirometry group change in FEV1 +5 ± 207 ml/yr in statin users change in FEV1–86 ± 168 ml/yr in control (p < 0.0001) change in FVC +33 ± 452 ml/yr in statin users change in FVC–150 ± 328 ml/yr in control (p < 0.0001) |
| Lee T-M, et al., Taiwan, 2008 [19] | No difference in pulmonary function parameters in statin users         | Pravastatin group: FEV1% at baseline 51 ± 18, at follow-up 55 ± 19 Placebo group: FEV1% at baseline 56 ± 13, at follow-up 55 ± 14, p > 0.05 |
| **Exercise capacity**         |                                                                         |                                               |
| Lee T-M, et al., Taiwan, 2008 [19] | Improvement in exercise time in statin users                             | Pravastatin group: exercise time in s at baseline 599 ± 323, at follow-up 922 ± 328 Placebo group: exercise time in s at baseline 608 ± 273, at follow-up 609 ± 180, p < 0.05 |
| **Borg dyspnea score after exercise tests** |                                                                         |                                               |
| Lee T-M, et al., Taiwan, 2008 [19] | Lesser degree of dyspnea after exercise in statin users                 | Pravastatin group: Borg dyspnea score at baseline 7.0 ± 0.8, at follow-up 4.0 ± 0.7 Placebo group: Borg dyspnea score at baseline 6.9 ± 0.8, at follow-up 6.9 ± 1.0, p < 0.05 |
| **CRP/IL-6 levels**           |                                                                         |                                               |
| Lee T-M, et al., Taiwan, 2008 [19] | Decrease in CRP/IL-6 levels in statin users                             | Pravastatin group: CRP (mg/l) at baseline 3.94 ± 3.54, at follow-up 3.85 ± 2.56 Placebo group: CRP (mg/l) at baseline 4.06 ± 2.67, at follow-up 2.66 ± 2.49, p < 0.05 |
mortality in COPD patients that underwent elective vascular surgery [21] and the interventional study by Lee et al. [19] gave information on smoking status of participants, but did not include subgroup analysis based on smoking status.

Cardiovascular risk profile

In the RCT by Lee et al. [19] no characteristics of the patients regarding cardiovascular risks were described. Mancini et al. [25] looked at COPD patients with different cardiovascular risk profiles. One cohort consisted of revascularized patients (percutaneous coronary angioplasty and/or bypass grafting), whereas a second cohort specifically excluded any patients with a myocardial infarction in the five years preceding cohort entry. The study found that the risk reduction for COPD hospitalizations and all-cause mortality with statin treatment was similar in both groups. However, there was no apparent beneficial effect on prevention of myocardial infarction in the low cardiovascular risk group. In the Norwegian retrospective cohort study by Søyseth et al. [22] nearly 30% of all study patients had diagnosed ischaemic heart disease with a significantly higher proportion in the statin group (approximately 60%). About 20% of all patients had congestive heart failure. Adjusted mortality was lower in statin users than non-users in both subgroups and most of the other comorbidity subgroups. No effect modification on statins by ischaemic heart disease or congestive heart failure was shown.

Figure 2

Forest plot of effect estimates of statins for ORs, HRs and RRs. RR = Risk ratio, HR = Hazard ratio, OR = Odds Ratio. Where available, adjusted estimates (OR, HR, RR) were used. Values less than 1 indicate a better outcome with statin therapy. Box size is proportional to precision of the estimate. * Mortality was only given for the whole cohort, which included 24% patients with restrictive rather than obstructive spirometry finding. ** 10-year mortality (mortality at 30 days not shown).
**Statin treatment**

Information on statin treatment including type of statin, dosage, treatment duration and adherence to treatment was very variable.

Three of the observational studies gave details on the types of statins used. In the study by Keddissi et al. [26] approximately 80% of statin users received simvastatin, and the remainder received lovastatin, atorvastatin and fluvastatin. In the study by Blamoun et al. [27] atorvastatin was the most common statin used (52%), followed by simvastatin (24%), lovastatin (10%), pravastatin (8%) and fluvastatin (6%). A third cohort study stated that statins included fluvastatin, simvastatin, pravastatin, atorvastatin, and rosuvastatin with no information on the distribution [21]. The Japanese population-based analysis stated that during the study period pravastatin, simvastatin, atorvastatin, and fluvastatin were commercially available in Japan, but no information on relatively prevalence of use was provided [23].

The study by Frost et al. which included all drugs in the statin class was one of two retrospective studies to include information about the dose of statins used [20]. The usual minimum prescribed dose was found to be 10 mg/d. Statin exposure to any statin was classified into low daily dose (<4 mg/d) and moderate daily dose (≥ 4 mg/d) for any type of statin, averaged over a three month to one year period. The fact that the cut off between low and moderate daily dose lay below the minimum prescribed dose indicated poor compliance. This study suggested a dose-dependent variation of response. The Dutch cohort study used a more sophisticated dosage classification [21]. The dosage of statin therapy was converted to no dose, low dose (<25%), and intensified dose (≥ 25%) of the maximum recommended therapeutic dose. Low dose statin treatment had no beneficial effect on short-term mortality in COPD patients. However, an intensified dose was associated with improved short-term survival. Both low-dose and intensive statin therapy were associated with improved long-term survival in patients with COPD. In the RCT the treatment group received pravastatin 40 mg daily over 6 months [19]. In the retrospective studies duration of treatment varied from at least one prescription in the 60 days prior to the index date [25] to at least 90 days of cumulative statin exposure prior to death or withdrawal [20]. Any FDA approved statins had to be used for at least 3 months prior the last pulmonary function test in the study by Keddissi et al. [26]. This study described a trend towards an association between the change in FEV1 and FEV and the duration of treatment with statins, but this did not reach statistical significance.

**Discussion**

The aim of this review was to evaluate evidence of beneficial effects of statin treatment in patients with COPD to determine implications for future studies. We assessed current evidence that statins may alter the natural course of COPD. We identified several observational studies that suggest a benefit of statin treatment on various clinically-relevant endpoints including all-cause mortality, deaths from COPD, respiratory-related urgent care, COPD exacerbations, intubations for exacerbations of COPD and lung function decline in COPD patients. There is evidence from one randomized controlled trial that exercise capacity is increased and dyspnea after exercise is decreased in COPD patients treated with statins.

There are certain limitations with the present systematic review. We deliberately did not use stringent selection criteria as we were aware that current evidence from research in this area is sparse. This resulted in heterogeneity across the selected studies with respect to study design, target population (different definitions for COPD), interventions (statin types, dosage, duration of treatment) and outcomes assessed. We did not include non-English-language papers, thereby possibly limiting the scope of included studies. As in any systematic review, publication bias was a concern, possibly leading to overestimation of the associations of statin treatment with favourable outcomes in COPD.

One important question, which is a matter of ongoing debate, is whether statins exhibit a beneficial effect in COPD because they affect cardiovascular comorbidities as opposed to having a direct disease-modifying effect on COPD. Søyseth et al. hypothesized that statins might improve all-cause mortality in COPD because many COPD patients probably have unrecognized ischemic heart disease [22]. Cardiovascular disease is increased in COPD patients due to various shared risk factors (e.g., smoking, obesity, diabetes), and there also seems to be a possible synergy between cardiovascular events and pulmonary inflammation [28]. The inflammation that is associated with atherosclerosis and atherothrombosis may be worsened by the systemic inflammatory component of COPD. Studies that have examined the effects of air pollution have previously suggested an association between airways inflammation and cardiovascular events [29,30]. However, the finding by Keddissi et al. that use of statins was associated with an attenuated decline in lung function and a lower incidence of respiratory-related ED-visits and/or hospitalizations in patients with obstructive lung disease implies that statins may have a direct disease-modifying effect on COPD [26].

It is assumed that the observed benefits of statins in patients with COPD derive at least partially from the drugs’ anti-inflammatory properties. However, none of the analysed retrospective studies that assessed the effect of statins on outcomes in COPD has examined the correlation between change in inflammatory markers and
those outcomes. In their RCT Lee et al. found that pravastatin caused a significant mean decrease in hs-CRP over the course of the study, but about a fifth of patients actually had an increase in hs-CRP. As expected, they found evidence of a floor effect. That is, those with higher baseline CRP levels (>3 mg/L) had a significant decrease in hs-CRP after statin treatment, whereas no changes in hs-CRP was observed in patients with low baseline CRP levels (<3 mg/L) [19]. In this study, significant improvement in exercise capacity in the statin treatment group correlated with decreasing CRP levels. However, no effect of pravastatin on lung function decline was found. The lack of effect on lung function in this RCT contrasts with observed inverse relationship between CRP and lung function in cross-sectional studies [31-33]. It is possible that the study period of 6 months was too short to reveal a significant effect of statins on lung function in this trial.

There are data to show that CRP levels are a predictor of COPD morbidity and mortality [34], and statins have been shown to reduce serum levels of CRP [35]. COPD patients with high baseline CRP levels (in a stable condition) could therefore be a subgroup to benefit most from statin treatment not just in regard to attenuated lung function decline, but also improved mortality. The recently published JUPITER study showed that rosuvastatin significantly reduced the incidence of major cardiovascular events in apparently healthy persons without hyperlipidemia but with elevated CRP levels [36]. However, besides the anti-inflammatory action, other possible effects of statins, e.g. anti-oxidant action, may be partially responsible for the apparent beneficial effect in COPD patients.

Current evidence is insufficient to determine whether smoking status influences the beneficial effects of statin therapy. Yet interestingly, present data, including the study by Alexeiff et al. [16], suggest that statins exhibit beneficial effects in current smokers as well as those who are not currently smoking.

Different statins could possess different modes of action, with resulting variations in outcomes. The lack of information on the effects of specific statins in most of the reviewed observational studies precludes further detailed analysis. Kienener et al. showed that the differential actions of statins are, in part, related to their lipophilicity. Lipophilic statins such as simvastatin and atorvastatin have the greatest anti-inflammatory potential [37]. No difference in FVC or FEV1 decline was seen between the different statins in the study by Keddissi et al. where 80% of patients received simvastatin, and the other patients received either lovastatin, atorvastatin or fluvastatin [26]. However, all those statins are lipophilic, whereas pravastatin, which was used in the RCT by Lee et al. [19] is hydrophilic. This might be a reason for the different effects of statin treatment on lung function decline in those two studies.

The relation of duration and dose of statin therapy to clinical outcomes in COPD or anti-inflammatory effects is unclear. A study of 107 hypercholesterolemic patients treated with simvastatin for 6 weeks showed a significant decline in cytokine levels; however, greater reductions were observed after 6 months [38]. Keddissi et al. described a trend towards an association between the change in FEV1 and FEV and the duration of treatment with statins, but this did not reach statistical significance. Although one of the studies demonstrated a dose-dependent gradient in response [20], the precise dose dependency of effect remains unclear. Also, because statin therapy compliance is thought to be poor [39], assessment of adherence to treatment (e.g. by measuring lipid profiles) is essential in statin studies.

**Conclusion**

In summary, our review shows that treatment with statins may have beneficial effects in patients with COPD, possibly reducing all-cause mortality, deaths from COPD, respiratory-related urgent care, COPD exacerbations, intubations for exacerbations of COPD and lung function decline and improving exercise capacity. While statins seem to influence systemic inflammation and cardiovascular morbidity in COPD patients, it appears likely that they also directly target airways inflammation. Types of statins, dosage and treatment duration necessary to exhibit a pleiotropic effect remain unclear. Most of the available data are based on observational studies and randomized controlled trials are urgently needed to evaluate the therapeutic effect of statins in COPD.

**Abbreviations**

COPD: chronic obstructive pulmonary disease; CRP: C-reactive protein; ED: Emergency Department; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; HR: Hazard ratio; hs-CRP: high-sensitivity C-reactive protein; OR Odds ratio; RCT Randomized controlled trial; RR: Risk Ratio.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

CCD and GBM contributed to the design of the study, data analyses and write-up of the manuscript. KKW contributed to data analyses and write-up of the manuscript. CCD and KKW collected the data. All authors read and approved the final manuscript.
Additional material

Additional file 1

Literature search strategy. The data provided represent the Ovid SP literature search strategy for Medline and Embase. Click here for file

http://www.biomedcentral.com/content/supplementary/1471-2466-9-32-S1.doc

Acknowledgements

We thank the National Health and Medical Research Council Centre of Clinical Research Excellence in Respiratory and Sleep Medicine, Australia, for providing funding for Claudia Dobler. The funding is independent of this specific study.

References

1. Murray CL: Alternative visions of the future: projecting mortality and disability. In The Global Burden of Disease Edited by: Murray CJL, Lopez AD, Hoekstra PJ, University Press; 1996:1-187.

2. Anthonisen NR, Skanes MA, Wise RA, Manfreda J, Kanner RE, Connett JE. Lung Health Study Research Group: The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005, 142:233-239.

3. Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981, 1:681-688.

4. Nocturnal Oxygen Therapy Trial Group: Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980, 93:391-398.

5. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Forarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeiffer MA, Taubert KA, AHA/ACC; National Heart, Lung, and Blood Institute: AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006, 113:2363-2372.

6. Barnes PF, Shapiro SD, Pauwels RA: Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003, 22:672-688.

7. Gan WQ, Man SF, Senthilselvan A, Sin DD: Simvastatin inhibits cigarette smoke-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med 2005, 172:987-993.

8. Palinski W: New evidence for beneficial effects of statins unrelated to lipid lowering. Arterioscler Thromb Vasc Biol 2001, 21:3-8.

9. Davignon J, Leiter LA: Ongoing clinical trials of the pleiotropic effects of statins. Vasc Health Risk Manag 2005, 1:29-40.

10. Bonetti PO, Lerman LO, Napoli C, Lerman A: Statin effects beyond lipid lowering: are they clinically relevant? Eur Heart J 2003, 24:225-248.

11. Almg Y, Shefer A, Novack V, Maimon N, Barski L, Eizinger M, Finger M, Zeller L, Danon A: Prior statin therapy is associated with a delayed rate of severe sepsis. Circulation 2004, 110:381-385.

12. Mortensen EM, Restrepo MI, Anzueto A, Pugh J: The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Rev 2005, 6:82.

13. Lundh A, Gotzsche PC: Recommendations by Cochrane Review Groups for assessment of the risk of bias in studies. BMC Med Res Methodol 2008, 8:22.

14. Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, Poole C, Schleselman JJ, Egger M: STROBE Initiative: Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med 2007, 4:e297.

15. Menkes D, Nair A, Melderman KT, Fleming D, Barnes M, Lipworth BJ: Simvastatin does not exhibit therapeutic anti-inflammatory effects in asthma. J Allergy and Clin Immunol 2007, 119:328-335.

16. Johnson BA, Lacoao AT, Zeeli A, McCurry KR, Duncan SR: Statin use is associated with improved function and survival of lung allografts. Am J Respir Crit Care Med 2003, 167:1271-1278.

17. Lee TM, Lin MS, Chang NC: Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am J Cardiol 2008, 101:530-535.

18. Frost FJ, Petersen H, Trollestrup K, Skipper B: Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007, 131:1006-1012.

19. van Gestel YR, Hoeks SE, Sin DD, Simsek C, Welten GM, Schouten OJ, Mertens RJT, Pauwels RA: Effect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease. Am J Cardiol 2008, 102:192-196.

20. Soysich V, Brekke PH, Smith P, Omland T: Statin use is associated with reduced mortality in COPD. Eur Respir J 2007, 29:279-283.

21. Ishida W, Kajiwara T, Ishii M, Fujifura F, Taneichi H, Takebe N, Takanashi K, Kaneko Y, Segawa I, Inoue H, Satoh J: Decrease in mortality rate of chronic obstructive pulmonary disease (COPD) with statin use: a population-based analysis in Japan. Tohoku J Exp Med 2007, 212:265-273.

22. Global Initiative for Chronic Obstructive Lung Disease: Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO workshop report. National Heart, Lung, and Blood Institute, Bethesda, 2001; NIH Publication No 2001;1-100.

23. Mancini GB, Emman M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM: Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. Am J Cardiol 2006, 47:2554-2560.

24. Kedissi J, Younis W, Chbeir EA, Daher NH, Demaika TA, Kinase-witz GT: The use of statins and lung function in current and former smokers. Chest 2007, 131:1764-1771.

25. Blamoun AI, Batty GN, DeBari VA, Rashid AO, Sheikh M, Khan MA: Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int J Clin Pract 2008, 62:1373-1378.

26. Sin DD, Man SF: Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003, 107:1514-1519.

27. Peters A, Dockery DW, Muller JE, Mittleman MA: Increased particulate air pollution and the triggering of myocardial infarction. Circulation 2001, 103:2810-2815.

28. Suwa T, Hogg JC, Quinlan KB, Ohgami A, Vincent R, van Eeden SF: Particulate air pollution induces progression of atherosclerosis. J Am Coll Cardiol 2002, 39:935-942.

29. Aronson D, Roterman I, Yigla M, Kernar A, Avizohar O, Sella R, Bartha P, Levy Y, Markiewicz W: Inverse association between pulmonary function and C-reactive protein in apparently healthy subjects. Am J Respir Crit Care Med 2006, 174:626-632.

30. Fogarty AV, Jones S, Britton JR, Lewis SA, McKeever TM: Systemic inflammation and decline in lung function in a general population: a prospective study. Thorax 2007, 62:515-520.

31. Ziaabian R, Kony S, Driss F, Lefaivre B, Soudan D, Pin I, Neukirch F, Zureik M: Change in C-reactive protein levels and FEV1 decline: a longitudinal population-based study. Respir Med 2006, 100:2112-2120.

32. Dahl M, Vestbo J, Lange P, Bojesen SE, Thybjaerg-Hansen A, Nordestgaard BG: C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175:250-255.

33. Prasad K: C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev 2006, 24:33-50.
36. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koentig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. JUPITER Study Group: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med* 2008, 359:2195-2207.

37. Kiener PA, Davis PM, Murray JL, Youssef S, Rankin BM, Kowala M: Stimulation of inflammatory responses in vitro by lipophilic HMG-CoA reductase inhibitors. *Int Immunopharmacol* 2001, 1:105-118.

38. Rezaie-Majd A, Maca T, Bucek RA, Valen P, Muller MR, Husslein P, Kashani-pour A, Minar E, Baghestanian M: Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. *Arterioscler Thromb Vasc Biol* 2002, 22:1194-1199.

39. Wei L, Wang J, Thompson P, Wong S, Struthers AD, MacDonald TM: Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. *Heart* 2002, 88:229-233.

**Pre-publication history**

The pre-publication history for this paper can be accessed here:

[http://www.biomedcentral.com/1471-2466/9/32/prepub](http://www.biomedcentral.com/1471-2466/9/32/prepub)